secwatch.observer — SEC 8-K summary
======================================

Issuer:     STRATA Skin Sciences, Inc. (SSKN)
CIK:        0001051514
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001140361-24-046508
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

STRATA Skin Sciences Q3 rev $8.8M, first non-GAAP operating profit since 2018
-----------------------------------------------------------------------------

- Revenue $8.8M (-1% YoY); recurring revenue $5.4M (+2% YoY); gross margin 60.3% (up from 56.0% YoY).
- Non-GAAP operating profit $128K (excl. $1.8M NY tax accrual); first since 2018 refinancing.
- Net loss narrowed to $0.3M ($0.08/sh) from $1.1M ($0.30/sh) in Q3 2023; cash $8.4M.
- XTRAC domestic base 873 (down from 882 Q2); TheraClear X base 135 (up from 117 Q2).
- Designated John Gillings (VP Finance) as principal financial & accounting officer; raised $2.1M in July equity offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1051514/000114036124046508/0001140361-24-046508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1051514/000114036124046508/ef20038566_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-046508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer